Compare IDEXX Laboratories, Inc. (IDXX) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Remitly Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $572.06 (market cap $46.22B), while Remitly Global Inc trades at $23.67 (market cap $4.97B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.3× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | RELY | |
|---|---|---|
Market Cap | $46.22B | $4.97B |
Sector | Health | Technology |
52-Week High | $766.68 | $25.93 |
52-Week Low | $526.44 | $12.20 |
Enterprise Value | $47.12B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
RELY trades at $23.14, down 5.24% over 24 hours, but maintains a bullish technical signal with key support at $22. The company reported strong Q2 2026 results, beating EPS estimates with $0.93 actual versus $0.12 expected, and revenue growth of 20% year-over-year. Profitability has improved significantly, with net income margin reaching 16.85% in 2026 from negative margins in prior years. Recent news highlights expansion into new financial services like the Global Card and regulatory approvals in the UAE.
The outlook is positive, driven by robust earnings growth, market share gains, and strategic initiatives beyond core remittances. Risks include competitive pressures and execution of new business lines. Analyst consensus is strongly bullish with a $31 price target, suggesting substantial upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
